Key Ingredients
Sacubitril 49 mg enhances protective natriuretic peptide activity by inhibiting neprilysin, while Valsartan 51 mg blocks angiotensin II–mediated vasoconstriction, together improving cardiac output and reducing disease progression in heart failure.
Benefits
Reduces Risk of Hospitalization
Lowers the likelihood of repeated hospital admissions due to worsening heart failure.
Improves Survival Outcomes
Clinically proven to reduce cardiovascular mortality in chronic heart failure patients.
Enhances Heart Function
Improves cardiac efficiency by reducing pressure overload on the heart.
Comprehensive Heart Failure Management
Used alongside standard heart failure medications for optimal control.
Well-Tolerated Long-Term Therapy
Suitable for chronic use under medical supervision.
Usage Instructions
Take the tablet exactly as prescribed by a healthcare professional. Regular monitoring of blood pressure, kidney function, and potassium levels is recommended.
Side Effects
May include low blood pressure, dizziness, increased potassium levels, kidney function changes, or cough. Seek medical advice if symptoms persist or worsen.
General Information
- Form: Tablet
- Strength: 100 mg
- Composition: Sacubitril 49 mg + Valsartan 51 mg
- Brand: VADASAC 100
- Packaging Size: 2 × 14 Tablets
- Packaging Type: Strips
- Indications: Chronic heart failure
- Availability: In Stock
- Country of Origin: India
Globus Labs brings you WHO-GMP–certified, high-quality Sacubitril 49 mg & Valsartan 51 mg Tablets IP (100 mg) sourced from reputed pharmaceutical manufacturers. VADASAC 100 is formulated to deliver safe, potent, and clinically trusted support.
